FMS Overview

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.

Wall Street analysts forecast FMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is25.00 USD with a low forecast of 22.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Fresenius Medical Care AG revenue for the last quarter amounts to 5.90B USD, increased 8.82

Fresenius Medical Care AG. EPS for the last quarter amounts to 1.33 USD, increased 454.17

Fresenius Medical Care AG (FMS) has 109698 emplpoyees as of March 11 2026.

Today FMS has the market capitalization of 13.47B USD.